NDA 021026 · Mylan
Vusion
Miconazole Nitrate, White Petrolatum, Zinc Oxide · Topical
Last checked: Nov 20, 2026Latest source record: Aug 29, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
Feb 16, 2006
Approved uses
1
Original approval plus efficacy supplements
Registered trials
36
8 Phase 3, 0 recruiting
FAERS reports
65
17 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 15, 2018.
• VUSION Ointment is indicated for adjunctive treatment of diaper dermatitis when complicated by documented candidiasis (microscopic evidence of pseudohyphae and /or budding yeast) in immunocompetent pediatric patients 4 weeks and older. ( 1.1 ) • VUSION Ointment should not be used as a substitute for frequent diaper changes. ( 1.1 ) • VUSION Ointment should not be used to prevent the occurrence of diaper dermatitis, since preventative use may result in the development of drug resistance. ( 1.2 ) 1.1 Indication VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes. VUSION should not be used as a substitute for frequent diaper changes. 1.2 Limitations of Use The safety and efficacy of VUSION have not been demonstrated in immunocompromised patients, or in infants less than 4 weeks of age (premature or term). The safety and efficacy of VUSION have not been evaluated in incontinent adult patients. VUSION should not be used to prevent the occurrence of diaper dermatitis, such as in an adult institutional setting, since preventative use may result in the development of drug resistance.
Mechanism: The miconazole component of VUSION is an antifungal agent [see Clinical Pharmacology (12.4) ]. The mechanism of action of white petrolatum and zinc oxide for the adjunctive treatment of diaper dermatitis is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- VUSION · MICONAZOLE NITRATE 0.25%; WHITE PETROLATUM 81.35%; ZINC OXIDE 15% · OINTMENT, TOPICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Miconazole Nitrate" as an intervention, any sponsor and status, largest first.
- Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious VaginitisPivotal-lookingCompleted
Laboratoire Innotech InternationalIndustry
NCT02515656 · 661 participants · Start Sep 2015 · Primary completion Aug 2016
Drug: POLYGYNAX®; GYNODAKTARIN® and 1 more · For: Vaginitis
Sites: Prague, Czechia; Lyon, France; Belgrade, Serbia · 4 sites in all
- An Efficacy Study of a New Formulation of Ketoconazole 2% Cream in Patients With Tinea Pedis, Commonly Known as Athlete's FootPivotal-lookingTerminated
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT01110330 · 583 participants · Start Jul 2007 · Primary completion Oct 2008
Drug: Placebo cream; Ketoconazole 2% cream (formulation F012) (Nizoral) and 1 more · For: Tinea Pedis
Sites: Bydgoszcz, Poland; Lodz, Poland; Lublin, Poland · 11 sites in all
- Efficacy and Safety Study of Miconazole Lauriad to Treat Oropharyngeal Candidiasis in HIV PatientsPivotal-lookingCompleted
Valerio TherapeuticsIndustry
NCT00390780 · 578 participants · Start Jul 2006 · Primary completion Dec 2007
Drug: miconazole Lauriad; Clotrimazole · For: HIV Infections
Sites: Birmingham, Alabama; Los Angeles, California; Oakland, California · 27 sites in all
- Efficacy and Safety Study of Miconazole Oil Versus Vehicle on Fungal Infection of the Ear Canal (Otomycosis)Pivotal-lookingCompleted
Hill Dermaceuticals, Inc.Industry
NCT04432376 · 382 participants · Start Jul 8, 2020 · Primary completion Nov 1, 2021
Drug: miconazole 2% oil; vehicle oil · For: Otomycosis
Sites: Chula Vista, California; La Jolla, California; Roseville, California · 12 sites in all
- Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative WomenPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT01230814 · 234 participants · Start Apr 2011 · Primary completion Aug 2013
Drug: Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate); Placebo · For: Bacterial Vaginosis; Candidiasis; Trichomoniasis
Sites: Birmingham, Alabama; Mombasa, Kenya; Nairobi, Kenya · 4 sites in all
Stiefel, a GSK CompanyIndustry
NCT00702507 · 200 participants · Start May 2007 · Primary completion Dec 2010
Drug: 0.25 % Miconazole Nitrate Ointment · For: Diaper Rash
Sites: San Diego, California; Coral Gables, Florida; Miami, Florida · 8 sites in all
- Validation of a Novel Diagnostic, Prognostic Assay for Bacterial VaginosisPivotal-lookingStatus unknown
Wayne State UniversityAcademic, hospital or other
NCT02185456 · 200 participants (planned) · Start Sep 2014 · Primary completion Jan 2016
Drug: 750 mg metronidazole/ 200 mg miconazole vaginal suppository; Standard of care · For: Bacterial Vaginosis
Sites: Detroit, Michigan
- Comparative Study of Topical Oxiconazole 1% Cream Versus Clotrimazole 1% Cream in the Treatment of DermatophytosisPivotal-lookingCompleted
Shalamar Institute of Health SciencesAcademic, hospital or other
NCT07718685 · 164 participants · Start Jan 1, 2025 · Primary completion Jun 30, 2025
Drug: Oxiconazole Nitrate Cream; Clotrimazole Cream · For: Dermatophytoses
Sites: Lahore, Pakistan
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective13
- rash6
- off label use5
- pyrexia5
- accidental exposure4
- application site erythema4
- erythema4
- accidental exposure to product by child3
- condition aggravated3
- nausea3
- no adverse event3
- accidental exposure to product2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 1 |
| 2007 | 2 |
| 2010 | 13 |
| 2011 | 8 |
| 2012 | 7 |
| 2013 | 3 |
| 2015 | 3 |
| 2016 | 5 |
| 2017 | 9 |
| 2018 | 5 |
| 2019 | 8 |
| 2021 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vusion (Miconazole Nitrate/Zinc Ox/Pet)
2024 spending
$31K
Beneficiaries
23
52 claims
Per beneficiary
$1,351
$11.10 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $17,970 |
| 2021 | $59,052 |
| 2022 | $48,600 |
| 2023 | $34,876 |
| 2024 | $31,066 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Athlete's foot.
Crawford F · BMJ Clin Evid 2009 · Systematic Review
- Chemoprophylaxis of fungal deterioration of the Provox silicone tracheoesophageal prosthesis in postlaryngectomy patients.
van Weissenbruch R, Bouckaert S, Remon JP, et al. · Ann Otol Rhinol Laryngol 1997 · Clinical Trial, Comparative Study
- Efficacy and tolerance of metronidazole and miconazole nitrate in treatment of vaginitis.
Peixoto F, Camargos A, Duarte G, et al. · Int J Gynaecol Obstet 2008 · Clinical Trial, Phase III, Multicenter Study
- Treatment of vaginitis.
Kükner S, Ergin T, Ciçek N, et al. · Int J Gynaecol Obstet 1996 · Clinical Trial
- Residual antibacterial activity of canine hair treated with topical antimicrobial sprays against Staphylococcus pseudintermedius in vitro.
Mesman ML, Kirby AL, Rosenkrantz WS, et al. · Vet Dermatol 2016 · Clinical Trial
- Impact of vaginal microbiota on the clinical efficacy and long-term recurrence of ketoconazole suppositories in treating severe vulvovaginal candidiasis: a secondary analysis of a multicentre randomised trial.
Mi L, Zhang D · Front Cell Infect Microbiol 2025 · Multicenter Study, Randomized Controlled Trial
Sponsor: Mylan
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.